Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
CANTON, Mass., April 20, 2017 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present at the 42nd Annual Deutsche Bank Healthcare Conference in Boston. The presentation will take place at 10:40 a.m. ET on Wednesday, May 3, 2017 at the InterContinental Boston Hotel.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact: Alex Dasalla [email protected]
